Short Talks Selected from Proffered Abstracts

PR-01 **TRIM29 is required for basal bladder cancer invasive progression.** Alan Kelleher. University of Michigan, Ann Arbor, Michigan, United States.

PR-02 **Sarcomatoid Histological Variants of Canine Muscle-Invasive Bladder Cancer: Transcription Factor Activation Highlights Pathways of Epithelial-Mesenchymal Transformation Similar to Humans.** Karin Allenspach. University of Georgia, Athens, Georgia, United States.

PR-03 **T cell receptor repertoire and diversity are prognostic markers in bladder cancer.** Nanna Kristjánsvóttir. National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States.

PR-04 **Spatial proteomics and transcriptomics reveal an altered immune cell landscape in bladder cancer patients unresponsive to BCG treatment.** Trine Strandgaard. Aarhus University Hospital, Aarhus, Denmark.

PR-05 **Final results from a Phase I trial of intravesical chemoimmunotherapy with gemcitabine and Bacillus Calmette-Guérin (BCG) for patients with BCG-exposed high-grade non-muscle invasive bladder cancer.** Syed Alam. Memorial Sloan Kettering Cancer Center, New York, New York, United States.


PR-07 **Identifying targeted therapies for muscle invasive bladder cancer via STAG2 expression.** Sarah Athans. Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States.

PR-08 **Modulating the PPARγ pathway to augment NECTIN4-targeting chimeric antigen receptor (CAR) T cell therapy.** Jonathan Chou. UCSF, San Francisco, California, United States.

PR-09 **Exploring the functional consequences of APOBEC3-induced non-coding hotspot mutations in bladder cancer using massively parallel reporter assays and CRISPR-mediated base editing.** Rouf Banday. National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States.

PR-10 **Exploratory analysis of tumor tertiary lymphoid structures using a novel artificial intelligence-based approach in patients with muscle-invasive urothelial carcinoma from the CheckMate 274 trial.** Matthew Milowsky. Department of Urology, Radboud University, Nijmegen, Netherlands.

Poster Session A (To be presented on May 18 from 4:15-6:15 p.m. ET)


A002 Assessment of the Diagnostic Accuracy of Oncuria-Detect® for Detection of Upper Tract Urothelial Carcinoma. Toru Sakatani. Cedars-Sinai Medical Center, Los Angeles, California, United States.

A003 Characterization of circulating tumor cells from patients with metastatic bladder cancer. Mark Day. University of Michigan, Ann Arbor, Michigan, United States.

A004 Clinical test design affects tumor tissue and ctDNA FGFR gene status in metastatic urothelial cancer: a prospective study. David Müller. Department of Urology, University Hospital Basel, University of Basel, Switzerland; Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.


A006 Bladder cancer risk stratification with the Oncuria 10plex bead-based urinalysis assay using three different Luminex xMAP instrumentation platforms. Toru Sakatani. Cedars-Sinai Medical Center, Los Angeles, California, United States.


A008 Racial differences in characteristics and outcomes of adjuvant nivolumab for muscle-invasive urothelial carcinoma (MIUC) in the real-world setting. Regina Barragan-Carrillo. City of Hope Comprehensive Cancer Center, Duarte, California, United States.


A011 Bladder cancerization is linked to epithelial basalization and is reversed by EGF inhibition. Kris Prado. Stanford University School of Medicine, Palo Alto, California, United States.

A012 Kmt2c/d loss primes urothelium for tumorigenesis and redistributes Menin to bivalent promoters. Naitao Wang. Memorial Sloan Kettering Cancer Center, New York, New York, United States.
A013 **Functional and clinical consequences of hotspot non-coding mutations upstream of the LEPROTL1 gene in bladder cancer.** Kelly Butler. National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, Maryland, United States.

A014 **PIK3CA mutation might confer resistance to an FGFR inhibitor, erdafitinib, in urothelial cancer cells.** Seiji Arai. Gunma University Graduate School of Medicine, Maebashi, Japan.

A015 **Novel genetic driver for the genesis of muscle invasion in bladder cancer.** Sreenidhi Mohanvelu. Oklahoma State University, Stillwater, Oklahoma, United States.

A016 **NRF2 activation promotes a fitness disadvantage in normal urothelium and drives a basal-like phenotype.** Akihiro Hamada. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States.

A017 **Patient-reported experience related to aspects of quality of life after cystectomy from an exploratory focus group.** Andrea Ireland. Janssen Medical Affairs, a Johnson & Johnson company, Horsham, Pennsylvania, United States.

A018 **A case of Buschke-Löwenstein tumor with superimposed infection and associated urothelial carcinoma.** ALIYA KHAN. BROWARD HEALTH NORTH, Pompano Beach, Florida, United States.

A019 **TRIM29 enhances the invasion of bladder cancer cells by modulating the intermediate filament network and focal adhesions.** Yin Wang. University of Michigan, Ann Arbor, Michigan, United States.

A020/PR-01 **TRIM29 is required for basal bladder cancer invasive progression.** Alan Kelleher. University of Michigan, Ann Arbor, Michigan, United States.

A021 **The role of MGAT5 in sex-dependent regulation of CD8+ T cells in muscle-invasive bladder cancer.** Morgan Roberts. University of British Columbia, Vancouver Prostate Centre, Vancouver, British Columbia, Canada.

A022/PR-02 **Sarcomatoid Histological Variants of Canine Muscle-Invasive Bladder Cancer: Transcription Factor Activation Highlights Pathways of Epithelial-Mesenchymal Transformation Similar to Humans.** Karin Allenspach. University of Georgia, Athens, Georgia, United States.

A023 **Stratification of bladder cancer patients with the use of flow cytometry is increasing the diagnostic potential of molecular classifiers.** Bernhard Kiss. Inselspital, University Hospital of Bern, Bern, Switzerland.

A024 **Genomic peroxisome proliferator-activated receptor gamma (PPARG) study: A sponsored testing program to identify patients harboring genetic alterations in advanced UC in support of the FX-909 Phase 1 study.** Bijal Kakrecha. Flare Therapeutics, Cambridge, Massachusetts, United States.
A025 Integrating genomic alterations and histopathological features for enhanced risk stratification in non-muscle invasive bladder cancer. Melinda Lillesand. Stavanger University Hospital, Stavanger, Norway.

A026 PIN1 isomerase promotes the initiation and progression of bladder cancer through SREBP2-mediated cholesterol biosynthesis pathway. Xue Wang. Salk Institute for Biological Studies, La Jolla, California, United States.

A027 The role of nuclear receptors as promoters of luminal tumors and suppressors of basal/squamous tumors. Cathy Mendelsohn. Columbia University, New York, New York, United States.


Poster Session B (To be presented on May 19 from 4:15-6:15 p.m. ET)


B003 Preliminary Machine Learning Integration of DNA Methylation-Based Tumor Immune Microenvironment Deconvolution with Histopathological Slides for Bladder Cancer Prognostication. Joshua Levy. Cedars-Sinai Medical Center, Los Angeles, California, United States.


B005/PR-03 T cell receptor repertoire and diversity are prognostic markers in bladder cancer. Nanna Kristjánsdóttir. Department of Molecular Medicine, Aarhus University Hospital; Department of Clinical Medicine, Aarhus University, Aarhus C, Denmark.

B006 GSTT2 MODULATES IMMUNE ACTIVATION AND IMPACTS RESPONSE TO BCG IMMUNOTHERAPY IN BLADDER CANCER. Mugdha Patwardhan. National University of Singapore, Singapore, Singapore.


B008 High expression of the exhaustion markers PD1 and PD-L1 in non-muscle invasive bladder cancer is associated with poor outcome following Bacillus Calmette-Guérin immunotherapy. Tine Andreasen. Aarhus University Hospital, Aarhus C, Denmark.

B009 Targeting bladder cancer-macrophage interactions by SPARC peptides. Neveen Said. Wake Forest University School of Medicine, Winston Salem, North Carolina, United States.

B010 Tumor B8T expression stratifies overall survival in high risk muscle invasive urothelial carcinoma. Burles Johnson III. Johns Hopkins University Greenberg Bladder Cancer Institute, Baltimore, Maryland, United States.

B012 BET inhibition sensitizes preclinical models of bladder cancer to DDR inhibitors. Bhavika Chirumamilla. UNC Eshelman School of Pharmacy, Chapel Hill, North Carolina, United States.


B015/PR-05 Final results from a Phase I trial of intravesical chemoimmunotherapy with gemcitabine and Bacillus Calmette-Guérin (BCG) for patients with BCG-exposed high-grade non-muscle invasive bladder cancer. Syed Alam. Memorial Sloan Kettering Cancer Center, New York, New York, United States.


B017 Novel Mesothelin-Based CAR T Cells Targeting MUC16 as an Intravesical Bladder Cancer Therapy. Parwiz Abrahimi. Weill Cornell Medicine, New York, New York, United States.

B018 KDM6A and MTAP expression loss enable identification of a large fraction of low grade non-invasive urothelial neoplasia of the urinary bladder. Neele Heckmann. Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.


B023/PR-08 Modulating the PPARγ pathway to augment NECTIN4-targeting chimeric antigen receptor (CAR) T cell therapy. Jonathan Chou. UCSF, San Francisco, California, United States.

B025 **Luminal-to-basal phenotypic plasticity promotes invasive phenotypes in a live-imaging assay using patient-derived bladder tumor organoids.** Clementine Le Coz. Columbia University Irving Medical Center, New York City, New York, United States.

B026 **APOBEC3 promotes squamous differentiation via IL1A/AP-1 signaling.** Michael Sturdivant. University of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States.

B027 **The MAT2A inhibitor IDE397: a novel combination backbone for urothelial cancer subjects with MTAP deficiency.** Claire Neilan. IDEAYA Biosciences, South San Francisco, California, United States.